Clinical trials: Dupilumab
Eosinophilic Disorder, Food Allergy
Gastrointestinal STRING Test With Oral Immunotherapy
This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST).
- Trial name
- STRING (NCT04943744)
- Testing
- Entero-tracker, omalizumab, dupliumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Atopic Disorders, Eczema, Atopic
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).
- Trial name
- NCT03050151
- Testing
- Dupilumab, Auto-injector Device, Prefilled syringe
- Where
- 37 sites in United States
- Volunteers
- 176 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Esophagitis (EoE)
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic…
- Trial name
- EoE KIDS (NCT04394351)
- Testing
- Dupilumab
- Where
- 27 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis, Psoriasis
Molecular Signatures in Inflammatory Skin Disease
This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and…
- Trial name
- MSID (NCT03358693)
- Testing
- Anti-TNF, Anti-IL12/23, Anti-IL17
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Prof. Dr. Stephan Weidinger
Atopic Dermatitis
Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood
This comparative study analyzes the efficacy and safety of treatment of children from 6 years of age suffering from moderate to severe atopic dermatitis using an inhibitor of IL4, IL13 and classical immunosuppressants.
- Trial name
- NCT04895423
- Testing
- Methotrexate therapy, Mycophenolate mofetil therapy, Cyclosporine therapy
- Where
- Russia
- Volunteers
- 160 people
- Sponsor
- National Medical Research Center for Children's Health, Russian Federation
Atopic Dermatitis
Dupilumab Phase 4 Study
The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving…
- Trial name
- DRS (NCT03411837)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Northwestern University
Asthma
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma. Secondary Objectives: To evaluate the safety and tolerability of dupilumab.
- Trial name
- NCT02414854
- Testing
- Dupilumab, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol
- Where
- 389 sites in United States, Argentina and 20 more
- Volunteers
- 1,902 people
- Sponsor
- Sanofi
Asthma
Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)
Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study.
- Trial name
- NCT03560466
- Testing
- Dupilumab (SAR231893/REGN668), Asthma controller therapies (incl. prednisone/prednisolone), Asthma reliever therapies
- Where
- 81 sites in United States, Argentina and 16 more
- Volunteers
- 378 people
- Sponsor
- Sanofi
Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe.
- Trial name
- AIM4:Next Step (NCT06572228)
- Testing
- dupilumab, ICS/LABA
- Where
- 77 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691).
- Trial name
- NCT02134028
- Testing
- Dupilumab
- Where
- 365 sites in United States, Argentina and 25 more
- Volunteers
- 2,282 people
- Sponsor
- Sanofi
Chronic Spontaneous Urticaria
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
Primary Objective: This study aimed to demonstrate the efficacy of dupilumab in study participants with CSU who remained symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab…
- Trial name
- NCT04180488
- Testing
- Dupilumab SAR231893, non sedating H1-antihistamine
- Where
- 98 sites in United States, Argentina and 9 more
- Volunteers
- 397 people
- Sponsor
- Sanofi
Asthma; Eosinophilic, Asthma Chronic
Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
The goal of this study is to identify reliable, valid, easily measurable, interpretable, and useful biomarkers in peripheral blood and exhaled air by people with severe asthma for a more accurate description of the pathogenetic…
- Conditions
- Asthma; Eosinophilic, Asthma Chronic, Bronchial Asthma, Asthma, Bronchial
- Trial name
- NCT05270278
- Where
- Czechia
- Volunteers
- 89 people
- Sponsor
- Value Outcomes Ltd.
Cold Urticaria
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
Primary Objective: To demonstrate the efficacy of dupilumab in adult and adolescent participants with primary acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of an H1-antihistamine…
- Trial name
- NCT04681729
- Testing
- Dupilumab SAR231893, Non sedating H1-antihistamine
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
Asthma
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
- Trial name
- PANDA (NCT05347771)
- Testing
- Dupilumab
- Where
- 8 sites in United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
This is a Prospective, non-interventional (NIS) observational study in patients (≥6 years) with atopic dermatitis (AD) receiving dupilumab for the prospective evaluation of signs and symptoms, quality of life and disease control.
- Trial name
- PROTYPE2 (NCT06039241)
- Where
- 55 sites in Germany
- Volunteers
- 572 people
- Sponsor
- Sanofi
Eosinophilic Esophagitis (EoE)
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding…
- Trial name
- EoE-TOTs (NCT07112378)
- Testing
- dupilumab
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals